On April 27, 2023 Chimeric Therapeutics (ASX:CHM, "Chimeric" or the "Company"), the only ASX-listed clinical stage cell therapy company, reported that the Indian Patent Office has issued a patent covering certain applications of chimeric antigen receptor (CAR) technology using chlorotoxin (CLTX), including Chimeric’s clinical-stage CAR T asset CHM 1101 and preclinicalstage CAR NK asset CHM 1301 (Press release, Chimeric Therapeutics, APR 28, 2023, View Source [SID1234630605]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The India patent has been granted under patent number IN 424963, entitled "Chimeric antigen receptors containing a chlorotoxin domain."
In addition, the Israel Patent Office has issued an Official Notification Prior to Acceptance, a notice of allowance, for application IL 258670.
Chimeric holds the exclusive worldwide license to develop and commercialize IN 424963, IL 258670, and related patent applications filed in other global territories. Chimeric’s CEO and Managing Director Jennifer Chow said: "We are delighted to have patent protection granted for CLTX CAR therapies in India and shortly in Israel as we continue to expand the robust intellectual property portfolio underpinning our CLTX CAR pipeline assets."
About CHM 1101:
CHM 1101 (CLTX CAR T) is a first in class CAR T therapy that has the potential to address the high unmet medical need of patients with recurrent or progressive glioblastoma, patients who have a poor prognosis, with limited treatment options and a median survival of less than 1 year (Gallego. Curr Oncol, 2015).
CHM 1101 cells uniquely utilize chlorotoxin (CLTX), a 36-amino acid peptide derived from deathstalkerscorpion venom, as the tumour-targeting component of the chimeric antigen receptor (CAR). In preclinical models, CHM 1101 CAR T cells have been shown to bind more broadly and specifically to GBM cells than other targeting domains like EGFR, HER-2 or IL-13. CHM 1101 cells also demonstrated potent antitumor activity against glioblastoma while not exhibiting any off-tumor recognition of normal human cells and tissues, indicating a potentially optimal safety and efficacy profile.
CHM 1101 is currently being studied in an ongoing phase 1A clinical trial in recurrent / progressive glioblastoma at City of Hope Cancer Centre in California. Outcomes from the initial two dose levels of the Phase 1A trial have been previously presented and demonstrated patient safety with a disease stability rate of approximately 70%.